Therapeutic Trial of EPI -743 In Patients With Disorders of Energy Utilization or Oxidation-Reduction
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Vatiquinone (Primary)
- Indications Metabolic disorders; Mitochondrial disorders
- Focus Therapeutic Use
- 04 Apr 2018 Planned primary completion date changed from 1 Apr 2018 to 31 Oct 2018.
- 01 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Jan 2019.
- 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.